Six cases of daptomycin-non-susceptible Staphylococcus aureus bacteraemia in Singapore

References

1. Camargo I. L., Neoh H. M., Cui L., Hiramatsu K. 2008; Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype. Antimicrob Agents Chemother 52:4289–4299 [CrossRef]
   [Google Scholar]
2. Cubist Pharmaceuticals 2008; Cubicin (daptomycin). [package insert] Cubist Pharmaceuticals; Lexington, MA, USA:
3. Cui L., Tominaga E., Neoh H. M., Hiramatsu K. 2006; Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycin-intermediate Staphylococcus aureus . Antimicrob Agents Chemother 50:1079–1082 [CrossRef]
   [Google Scholar]
4. Enright M. C., Day N. P., Davies C. E., Peacock S. J., Spratt B. G. 2000; Multilocus sequence typing for characterization of methicillin-resistant and methicillin-sensitive clones of Staphylococcus aureus . J Clin Microbiol 38:1008–1015
   [Google Scholar]
5. Hsu L. Y., Loomba-Chlebicka N., Koh Y. L., Tan T. Y., Krishnan P., Lin R. T., Tee N. W., Fisher D. A., Koh T. H. 2007; Evolving EMRSA-15 epidemic in Singapore hospitals. J Med Microbiol 56:376–379 [CrossRef]
   [Google Scholar]
6. Ito T., Ma X. X., Takeuchi F., Okuma K., Yuzawa H., Hiramatsu K. 2004; Novel type V staphylococcal cassette chromosome mec driven by a novel cassette chromosome recombinase, ccrC . Antimicrob Agents Chemother 48:2637–2651 [CrossRef]
   [Google Scholar]
7. Jones T., Yeaman M. R., Sakoulas G., Yang S. J., Proctor R. A., Sahl H. G., Schrenzel J., Xiong Y. Q., Bayer A. S. 2008; Failures in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob Agents Chemother 52:269–278 [CrossRef]
   [Google Scholar]
8. Lee C. H., Wang M. C., Huang I. W., Chen F. J., Lauderdale T. L. 2010; Development of daptomycin nonsusceptibility with heterogeneous vancomycin intermediate resistance and oxacillin susceptibility in methicillin-resistant Staphylococcus aureus during high-dose daptomycin treatment. Antimicrob Agents Chemother 54:4038–4040 [CrossRef]
   [Google Scholar]
9. Mariani P. G., Sader H. S., Jones R. N. 2006; Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy. J Antimicrob Chemother 58:481–483 [CrossRef]
   [Google Scholar]
10. Maslow J., Slutsky A., Arbeit R. 1993; The application of pulsed-field gel electrophoresis to molecular epidemiology. In Diagnostic Molecular Microbiology: Principles and Applications pp 563–572 Edited by Persing H., Smith T., Tenover F., White T. Washington, DC: American Society for Microbiology;
    [Google Scholar]
11. Moise P. A., North D., Steenbergen J. N., Sakoulas G. 2009; Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus : facts and assumptions. Lancet Infect Dis 9:617–624 [CrossRef]
    [Google Scholar]
12. Sakoulas G., Alder J., Thauvin-Eliopoulos C., Moellering R. C. Jr, Eliopoulos G. M. 2006; Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 50:1581–1585 [CrossRef]
    [Google Scholar]
13. Sakoulas G., Brown J., Lamp K. C., Friedrich L. V., Lindfield K. C. 2009; Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and Experience. Clin Ther 31:1936–1945 [CrossRef]
    [Google Scholar]